Dracovich et al. developed the first reportedAb-PROTAC conjugateby attaching a BET degrader to an anti-C-type lectin-like molecule-1(CLL1) antibody.104 CLL-1 is an ideal targetfor an Ab-based therapy for AML, due to its high expression in leukemiccells, while being absent in normal hematopoietic stem cells.The authors synthesized a new potent BRD4 degrader, GNE-987 (21, Figure 11), by incorporating the VHL-binding moiety along with the structureof a potent BET inhibitor. This evidence concerns the gene CLEC12A and acute myeloid leukemia.